<DOC>
	<DOCNO>NCT02475824</DOCNO>
	<brief_summary>This single-center , prospective , randomize , double-blinded study consecutive patient refer ERCP . A recent study suggest addition dexmedetomidine midazolam-meperidine regimen ( MMD ) provide well sedative efficacy superior safety profile ERCP compare midazolam-meperidine regimen . Further study warrant compare MMD regimen propofol-based regimen . Randomization perform use computer-generated random allocation ratio 1:1 balance block 4 . A separate sedating nurse , n't participate study , person knowledge sedation regimen . This separate nurse repeat injection propofol complete questionnaire .</brief_summary>
	<brief_title>Midazolam With Meperidine Dexmedetomidine vs. Midazolam With Meperidine Propofol Sedation During ERCP</brief_title>
	<detailed_description>Study design This single-center , prospective , randomize , double-blinded study consecutive patient refer ERCP . Randomization perform use computer-generated random allocation ratio 1:1 balance block 4 . A separate sedating nurse , n't participate study , person knowledge sedation regimen . This separate nurse repeat injection propofol complete questionnaire . Inclusion criterion include consecutive patient schedule ERCP age 18-80 year . ( ASA class I-III ) Exclusion criterion follow ; 1 ) patient age &lt; 18years , 2 ) pregnancy , 3 ) American Society Anesthesiology ( ASA ) physical status class IV , V , 4 ) history allergy drug use , 6 ) history complication previous sedation , 5 ) hypoxemia ( baseline SaO2 ) &lt; 90 % , 6 ) hypotension ( baseline systolic blood pressure &lt; 90mmHg ) , 7 ) severe bradycardia ( heart rate &lt; 50/min ) and/or brady-dysrhythmias ( e.g . advanced heart block ) , 8 ) impair ventricular function ( left ventricular ejection fraction &lt; 30 % ) , 9 ) baseline respiratory rate &gt; 25 &lt; 10 breaths/min , 10 ) inability provide inform consent . Patients exclude final analysis procedure terminate early abandon anatomical reason ( i.e. , duodenal obstruction gastrectomy ) . Sedation protocol After randomization patient allocate group 1 2 , prepare endoscopy . All sedative analgesic use study administer trained sedative nurse endoscopist supervision . All participant receive IV bolus dose midazolam ( 0.06mg/kg , 50 % reduction patient age ≥70 ASA class III-IV ; Bukwang Pharm Co. , Seoul , Republic Korea ) meperidine ( 50mg . 25mg patient age ≥70 year ; pethidine HCL , Hana Pharm Co. , Seoul , Republic Korea ) . Repeated dose 10-20 mg propofol titrate achieve target level sedation . Maintenance sedation achieve repeated dos 5 20 mg propofol . The total dosage propofol ( include additional dos ) limit low upper bound 10mg 100mg , respectively . The target level sedation moderate sedation base ASA level . For patient allocate midazolam-meperidine-dexmedetomidine ( MMD ) group , midazolam ( 0.05 mg/kg , 30 % reduction patient age ≥70 ASA class III-IV ; Bukwang Pharm Co. , Seoul , Republic Korea ) meperidine ( 50mg . 25mg patient age ≥70 year ; pethidine HCL , Hana Pharm Co. , Seoul , Republic Korea ) give intravenously initiation sedation . In addition , continuous IV infusion dexmedetomidine ( 1ug/kg/h , Precedex ; Hospira , Seoul , Republic Korea ) administer 15 min ERCP till complete procedure . Thereafter , repeat dos 1 2 mg midazolam administer maintain moderate level sedation . For patient allocate midazolam-meperidine-propofol ( BPS ) group , midazolam meperidine give initiation sedation manner MMD group . Thereafter , repeat dos 10-20 mg propofol titrate achieve target level sedation . Maintenance sedation achieve repeated dos 5 20 mg propofol . The total dosage propofol ( include additional dos ) limit low upper bound 10mg 100mg , respectively . The target level sedation moderate sedation base ASA level . Medications monitor Intranasal supplemental oxygen ( 2L/min ) provide participant initiation sedation . Heart rate , electrocardiogram , peripheral oxygen saturation ( SaO2 ) , respiratory rate , end-tidal carbon dioxide ( EtCo2 ) constantly monitor . Non-invasive blood pressure ( NIBP ) automatically measure 3-minute interval . Sedation level assess record every 3 minute throughout procedure Modified Observer 's Assessment Alertness Sedation ( MOAA/S ) . Patients consider oversedated MOAA/S score 1 . MOAA/S , Modified Observe 's Assessment Alertness Sedation : 5-responds readily name spoken normal tone , 4-lethargic response name speak normal tone , 3-responds name call loudly and/or repeatedly , 2-responds mild prod shaking , 1-does respond mild prod shaking , 0-does respond noxious stimulus . If hypoxemia ( SpO2 &lt; 90 % ) observe sedation either group , O2 supplementation increase 2L/min oxygen saturation restore . If SpO2 drop &lt; 85 % &gt; 30 sec , despite patient stimulation interruption sedatives jaw thrust maneuver , antagonist midazolam ( flumazenil ) could inject procedure interrupt normalization oxygen saturation occur . During recovery , patient 's vital sign ( NIBP , SpO2 , heart rate ) , sedation level ( Gillham scale ) , speed recovery ( modified Aldrete score ) record 5-minute interval discharge recovery room . Gillham sedation scale ; 1-awake anxious , 2-awake anxious , 3-speech slur , 4-eyes close , respond speech , 5-eye close , respond shake , 6-unresponsive . Outcome measurement definitions The primary endpoint study rate cardiopulmonary complication frequency interruption ERCP procedures complication include ( 1 ) hypoxemia ( pulse oximeter oxygen saturation 90 % supplemental oxygen ) , ( 2 ) hypotension ( systolic blood pressure 90 mmHg ) , ( 3 ) bradycardia ( heart rate 50 beats/min ) . Procedure quality evaluate base therapeutic procedure outcome , include technical success total procedure time , procedure-related adverse event . If transient interruption procedure occur sedation-related complication , time subtracted procedure time . The endoscopist , blind method sedation , The secondary endpoint ease ERCP performance , speed recovery , patient satisfaction sedation . At end procedure , ease performance ERCP evaluate endoscopist use structured questionnaire . If full recovery confirm inpatient setting , patient satisfaction sedation pain intensity ERCP assess another independent assistant use 10-cm VAS scale ( 0=no pain/no satisfaction , 10=worst pain/full satisfaction )</detailed_description>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Meperidine</mesh_term>
	<criteria>Those scheduled ERCPs age 18 80 year American Society Anesthesiologists ( ASA ) classification I III ASA IV V History allergy drug use refuse participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ERCP</keyword>
	<keyword>Sedation</keyword>
	<keyword>safety</keyword>
</DOC>